Cardiak Ltd, a spinout from Imperial College, London and the Royal Brompton & Harefield Hospital, is looking for a buyer for its pre-clinically tested, fully implantable heart assist device.
The device has a number of novel features, including being easier to implant than existing devices, having no direct contact with the blood, and thus avoiding the requirement for anticoagulant therapy and with no leads passing through the skin, reducing the risk of infection.
The Board of Cardiak, following discussions with its shareholders and advisors is now seeking a sale of the assets of Cardiak via a bid process. On offer is:
- an intellectual property portfolio including 3 key patents filed in many key territories covering a novel axial shift impeller pump and its associated use as an extra aortic counterpulsation device.
- a number of prototype implantable extra-aortic counter-pulsation devices, power supplies and driver systems which have demonstrated excellent haemodynamic performance in direct comparison with the current performance standard for counter-pulsation; the intra-aortic balloon pump.
- technical details and specifications relating to the akpulsor device and the driver technology
- Cardiak brand image, internet domains and trademarks.